IMMIX
immix.xyz
Actively hiring
Stablecoins
Cryptocurrencies
Blockchain & Crypto
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
Crane Venture Partners
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
Crane Venture Partners Similar startupsby what they do, their industry and backers
Collect, convert, and settle payments between African currencies and USD/stablecoins. One API for onramp, offramp, and cross-border…
Cyclops is the all-in-one solution powering crypto and stablecoin solutions for payments companies.
UK-domiciled stablecoin issuer providing infrastructure for global businesses. Agant issues GBPA - digital pounds backed 1:1 with GBP.
The global financial account for freelancers. USD accounts, a global card, and stablecoin payouts, all in one app.
Global payments, named USD and EUR accounts, and native stablecoin support for companies. Swiss fintech membership, by invitation.
Stablecoin account for everyday money. Access USD, deposit stablecoins, send instantly, earn on your balance, and spend globally with a…
News
ImmixBio Reports 89% CR Rate, Potential 98% With NXC-201 In AL Amyloidosis
Immix Biopharma (IMMX) said an interim Phase 2 NEXICART-2 update showed an 89% complete response rate with investigational NXC-201 in relapsed/refractory AL amyloidosis.
Read more
Report
Immix Biopharma's NXC-201 Shows 89% Complete Response Rate In AL Amyloidosis
ImmixBio's NXC-201 posts 89% complete response rate in relapsed/refractory AL amyloidosis..
Read more
Report
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (
Read more
Report
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting...
- 100% (25/25) of new patients are either in complete response (CR) or MRD-negative (21/25 are in CR; remaining 4/25 are MRD-negative) -- To-date,...
Read more
Report
Immix Reports NXC-201 AL Amyloidosis Trial Results
Immix Biopharma (NASDAQ:IMMX) reports 89% complete response rate in Phase 2 NEXICART-2 trial of NXC-201 for relapsed or refractory AL amyloidosis.
Read more
Report
Pro access
Upgrade to see all 11 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.